JP2013508382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508382A5 JP2013508382A5 JP2012535319A JP2012535319A JP2013508382A5 JP 2013508382 A5 JP2013508382 A5 JP 2013508382A5 JP 2012535319 A JP2012535319 A JP 2012535319A JP 2012535319 A JP2012535319 A JP 2012535319A JP 2013508382 A5 JP2013508382 A5 JP 2013508382A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- methyl
- pharmaceutically acceptable
- dihydropyrido
- tetrahydropyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 tetrahydropyran-4-yl Chemical group 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25430809P | 2009-10-23 | 2009-10-23 | |
| US61/254,308 | 2009-10-23 | ||
| PCT/US2010/053295 WO2011050016A1 (en) | 2009-10-23 | 2010-10-20 | Akt inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508382A JP2013508382A (ja) | 2013-03-07 |
| JP2013508382A5 true JP2013508382A5 (enExample) | 2013-06-06 |
| JP5581390B2 JP5581390B2 (ja) | 2014-08-27 |
Family
ID=43467018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535319A Expired - Fee Related JP5581390B2 (ja) | 2009-10-23 | 2010-10-20 | Ａｋｔ阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8436002B2 (enExample) |
| EP (1) | EP2491032B1 (enExample) |
| JP (1) | JP5581390B2 (enExample) |
| KR (1) | KR101398268B1 (enExample) |
| CN (1) | CN102574852B (enExample) |
| AU (1) | AU2010310786B2 (enExample) |
| BR (1) | BR112012011328A2 (enExample) |
| CA (1) | CA2778291C (enExample) |
| EA (1) | EA020151B1 (enExample) |
| ES (1) | ES2465094T3 (enExample) |
| MX (1) | MX2012004780A (enExample) |
| WO (1) | WO2011050016A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2873654C (en) * | 2012-05-17 | 2021-06-22 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| WO2013173736A1 (en) | 2012-05-17 | 2013-11-21 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| CA2873658C (en) | 2012-05-17 | 2021-01-26 | Genentech, Inc. | Process for making amino acid compounds |
| PE20150725A1 (es) | 2012-05-17 | 2015-05-17 | Genentech Inc | Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este |
| NZ702950A (en) | 2012-05-17 | 2016-09-30 | Genentech Inc | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| US9315517B2 (en) * | 2012-11-16 | 2016-04-19 | Merck Patent Gmbh | Imidazol-piperidinyl derivatives as modulators of kinase activity |
| SG10201900954SA (en) | 2013-03-11 | 2019-02-27 | Merck Patent Gmbh | Heterocycles as Modulators of Kinase Activity |
| US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
| US10526660B2 (en) | 2013-09-12 | 2020-01-07 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
| GB201401198D0 (en) * | 2014-01-24 | 2014-03-12 | Bial Portela & Ca Sa | Process for the syntheis of substituted urea compounds |
| WO2015130585A1 (en) | 2014-02-28 | 2015-09-03 | Merck Sharp & Dohme Corp. | Method for treating cancer |
| MA45048A (fr) * | 2016-05-20 | 2019-03-27 | Taiho Pharmaceutical Co Ltd | Nouveau dérivé de 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one |
| CA3127884A1 (en) * | 2019-01-29 | 2020-08-06 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Akt inhibitor |
| CN115485276B (zh) * | 2020-05-15 | 2024-05-31 | 南京正大天晴制药有限公司 | 氘代akt激酶抑制剂 |
| JP7472391B2 (ja) * | 2020-07-22 | 2024-04-22 | 南京正大天晴制薬有限公司 | ジヒドロピリド［２，３－ｄ］ピリミジノン誘導体の塩及び結晶形 |
| CN115916350B (zh) * | 2020-07-22 | 2024-11-05 | 南京正大天晴制药有限公司 | Akt抑制剂的单位剂量组合物 |
| WO2022017449A1 (zh) * | 2020-07-22 | 2022-01-27 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| NL1004346C2 (nl) | 1996-10-23 | 1998-04-24 | Dsm Nv | Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel. |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US7767687B2 (en) * | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| MX2007016203A (es) | 2005-06-29 | 2008-03-10 | Compumedics Ltd | Ensamble de sensor con puente conductivo. |
| JP2009534456A (ja) * | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP3719018B1 (en) | 2006-04-25 | 2025-08-27 | Astex Therapeutics Ltd | Purine and deazapurine derivatives as pharmaceutical compounds |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| UA99284C2 (ru) * | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
-
2010
- 2010-10-20 JP JP2012535319A patent/JP5581390B2/ja not_active Expired - Fee Related
- 2010-10-20 EA EA201270590A patent/EA020151B1/ru not_active IP Right Cessation
- 2010-10-20 BR BR112012011328A patent/BR112012011328A2/pt not_active IP Right Cessation
- 2010-10-20 EP EP10774072.2A patent/EP2491032B1/en not_active Not-in-force
- 2010-10-20 ES ES10774072.2T patent/ES2465094T3/es active Active
- 2010-10-20 CN CN201080046941.9A patent/CN102574852B/zh not_active Expired - Fee Related
- 2010-10-20 KR KR1020127010282A patent/KR101398268B1/ko not_active Expired - Fee Related
- 2010-10-20 WO PCT/US2010/053295 patent/WO2011050016A1/en not_active Ceased
- 2010-10-20 US US13/391,895 patent/US8436002B2/en not_active Expired - Fee Related
- 2010-10-20 MX MX2012004780A patent/MX2012004780A/es active IP Right Grant
- 2010-10-20 AU AU2010310786A patent/AU2010310786B2/en not_active Ceased
- 2010-10-20 CA CA2778291A patent/CA2778291C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508382A5 (enExample) | ||
| JP2010540509A5 (enExample) | ||
| JP2009542613A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2013510124A5 (enExample) | ||
| ME01462B (me) | Vinilindazolilna jedinjenja" | |
| JP2006524660A5 (enExample) | ||
| WO2017193030A1 (en) | Modulators of the integrated stress pathway | |
| JP2019510798A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2009532452A5 (enExample) | ||
| HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2011500758A5 (enExample) | ||
| JP2011507896A5 (enExample) | ||
| JP2010241830A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| JP2014503567A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2014526549A5 (enExample) | ||
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| JP2015524450A5 (enExample) | ||
| JP2013505930A5 (enExample) | ||
| NZ601077A (en) | Use of an adrenal hormone-modifying agent |